Novan — Investor Presentation (November 2016)
25 slides from Novan's investor presentation, Nov 29, 2016
Slide 1: Corporate Presentation November 2016
Corporate Presentation November 2016 Exhibit 99.1
Slide 2: Forward Looking Statements
This presentation includes forward-looking statements that reflect our current views with respect to, among other things, our operations and financial performance. These forward-looking statements are included throughout this presentation. We have used the words “anticipate,” “assume,” “believe,” “c
Slide 3: Overview
Technology platform for transforming nitric oxide into new chemical entities and product candidates for a host of skin diseases SB204 – Phase 3 asset with top-line results expected 1Q 2017 Parallel Phase 3 pivotal trials initiated in 1Q 2016; NDA submission targeted for end of 2017 Robust clinical d
Slide 4: Experienced Leadership
Experienced Leadership Management Team Nathan Stasko, PhD Chief Executive Officer, Director Richard Peterson Chief Financial Officer Brian Johnson, MBA Chief Commercial Officer M. Joyce Rico, MD, MBA Chief Medical Officer Stan Hollenbach, JD VP, Research and Nonclinical Development Kevin Barber, PhD
Slide 5: Our Nitric Oxide Pipeline
Our Nitric Oxide Pipeline Our focus on these five indications targets disease burden in >150M individuals in the US and >1.5B individuals globally. Product Candidates Indication Target Preclinical / Phase 1 Phase 2 Phase 3 Anticipated Milestones SB204 Acne Vulgaris P. acnes, IL-1, IL-17 Report top l
Slide 6: Nitric Oxide Platform Overview
Nitric Oxide Platform Overview
Slide 7: Nitric Oxide Mechanisms of Action
Science – Breakthrough of the Year (1992) Nobel Prize in Medicine (1998) >100,000 peer reviewed manuscripts Broad Spectrum Antimicrobial Anti-bacterial Anti-viral Anti-fungal Immunomodulatory Agent Decreases key biomarkers for inflammation Inhibits T cell proliferation Results in NO-derived regulato
Slide 8: Nitricil Technology
Nitricil Technology Stable storage Drugable form of nitric oxide with shelf-life stability Therapeutic quantities High loading capacity previously unachievable “Tunability” pH-controlled hydrolysis that releases nitric oxide Engineered macromolecule Targets nitric oxide delivery to the skin Minimize
Slide 9: Formulation Science
Formulation Science Cosmetic Elegance FDA’s IID For Topical Use Irritation Potential Compatibility with Nitricil In vitro Release Shelf-life Stability Product Candidates (SB204) Nitricil based NCEs Our goal is to balance the need for safe and effective delivery of nitric oxide with physician and pat
Slide 10: Our Nitric Oxide Platform
Our Nitric Oxide Platform NVN1000 Nitric Oxide Proprietary chemistry that stores large amounts of nitric oxide in solid form Macromolecular NCEs Drug Candidates Indication specific formulations with differentiated nitric oxide release rates Formulation Science Nitricil Technology SB204 SB206 Over 10
Slide 11: Summary of Intellectual Property Portfolio
Summary of Intellectual Property Portfolio Covered Patent Life Issued Patents (Pending Applications) NitricilTM Technology Composition of Matter Family of Compounds – 8,282,967 NVN1000 Composition – 8,956,658 NVN4000 Composition – 8,962,029 Method of Manufacture to 2026 to 2032 US, Japan, Australia
Slide 12: SB204 Potential First-in-Class Topical for the Treatment of Acne
SB204 Potential First-in-Class Topical for the Treatment of Acne
Slide 13: Nitric Oxide and Acne
Nitric Oxide and Acne Hanna-Leena Kelhälä et al. PLoS One. 2014;9(8): e105238. Niedbala W et al. Proc Natl Acad Sci USA. 2011;108(22):9220-9225. Niedbala W et al. J Immunol. 2013;191(1):164-170. Qin M et al. J Invest Dermatol. 2015;135(11):2723-2731. P. acnes Excess sebum Inflammation Hyper-keratini
Slide 14: SB204
SB204 SB204 Activating Hydrogel NVN1000 Alcohol Gel SB204 is a once-daily, fast-acting, cosmetically elegant topical gel currently in Phase 3 clinical development for the treatment of acne vulgaris Potential first-in-class topical treatment that has shown evidence of efficacy against both inflammato
Slide 15: Phase 3 Pivotal Trial Design
1,300 patients per trial x 2 pivotals = 2,600 patients total 1:1 randomization, SB204 4% Once Daily vs Vehicle Once Daily 12 weeks of treatment Inclusion Criteria Ages 9 and up Minimum 20 and no more than 40 inflammatory lesions on the face Minimum 25 and no more than 70 non-inflammatory lesions on
Slide 16: SB206 Product Candidate for the Treatment of Viral Skin Infections
SB206 Product Candidate for the Treatment of Viral Skin Infections
Slide 17: Human Papilloma Virus (HPV) Associated Warts
Human Papilloma Virus (HPV) Associated Warts Prevalence HPV affects nearly 80 million Americans 14 million people become infected each year Over 100 subtypes, low and high risk strains Prevalence of warts in the US: Genital warts exceeds 500,000 people Common warts exceeds 3,000,000 people Infection
Slide 18: Phase 2 Clinical Study of SB206
Phase 2 Clinical Study of SB206 12 week treatment duration SB206 4% gel 2x/day SB206 4% gel 1x/day Vehicle gel 1x/day SB206 8% gel 1x/day Primary endpoint Secondary endpoints include: Proportion of patients at week 12 who are completely clear of warts present at baseline Proportion of patients at we
Slide 19: Phase 2 Patient Demographics and Disposition
Phase 2 Patient Demographics and Disposition Vehicle gel QD/BID (n = 27) SB206 4% gel BID (n = 12) SB206 4% gel QD (n = 24) SB204 8% gel QD (n = 14) SB204 12% gel QD (n = 30) Gender, n (%) Male 19 (70.4%) 6 (50.0%) 16 (66.7%) 12 (85.7%) 23 (76.7%) Female 8 (29.6%) 6 (50.0%) 8 (33.3%) 2 (14.3%) 7 (23
Slide 20: Treatment-Emergent and Application-Site Adverse Events
Phase 2 Treatment-Emergent and Application-Site Adverse Events Vehicle gel QD/BID (n = 27) SB206 4% gel BID (n = 12) SB206 4% gel QD (n = 23) SB204 8% gel QD (n = 14) SB204 12% gel QD (n = 30) General Disorders and Administration-Site Conditions 1 (4.2%) 6 (50.0%) 6 (26.1%) 1 (7.1%) 5 (16.7%) Burn 0
Slide 21: Primary Endpoint Complete Clearance of Baseline Warts
Phase 2 Primary Endpoint Complete Clearance of Baseline Warts (ITT & PP analyses) p=0.0099 p=0.0200 Solid (ITT) Lined (PP)
Slide 22: SB206 Research Collaborations
SB206 Research Collaborations In vitro and in vivo data generated with collaborators who are at the cutting edge of HPV disease pathology research. Dr. Neil Christensen, Professor of Pathology, and Microbiology and Immunology; Medical Director, Jake Gittlen Cancer Research Foundation Research Intere
Slide 23: Nitric Oxide Inhibition of Viral Replication
Nitric Oxide Inhibition of Viral Replication HPV-18 Infected Human Epidermis Grown in Culture BrdU Stain (mitotic index for rapidly dividing nuclei) Untreated Control 1.5 mg/mL NVN1000 qPCR analysis of HPV-18 viral copy number Large number of BrdU stained cells indicative of pervasive viral infectio
Slide 24: Dose Ranging of SB206 Compared to Topical Imiquimod
Dose Ranging of SB206 Compared to Topical Imiquimod Wild Type Virus E8 Mutant Virus The E8 mutant virus produces slower-growing and more clinically relevant papillomas than the Wild Type virus Dose responsive, pharmacologic effect of SB206 against papillomavirus in a Cottontail Rabbit model
Slide 25: Upcoming Milestones
Upcoming Milestones SB204 (Acne vulgaris) SB206 (Anti-viral) SB208 (Anti-fungal) Report TLRs from Phase 3 pivotal trials Report TLRs from Phase 2 clinical trial Commence Phase 2 anti-fungal program Targeted NDA Submission Report TLRs from 40 wk LTS Study Complete enrollment in both Phase 3 pivotal t